cancer-dubai-2019-scientifictracks

2 / 3

allied
academies
Page 29
December 05-06, 2019 | Dubai, UAE
29th International Conference on
14th International Conference on
Nursing Education and Research
Cancer and Cancer Therapy
Joint Event
&
Journal of Medical Oncology and Therapeutics | Volume 4
The potential importance of hyper cobalaminemia as a possible early marker in the
working diagnosis of malignancy and blood disorders
Abdou Shafik Mohamed Deyab
Alexandria University, Egypt
H ypercobalaminemia is defined by a rate of vitamin
B12 above 950pg/ml. The most obvious cause of
hypercobalaminemia is taking too much of the vitamin
in the form of supplements. Vitamin B12 is generally
not considered toxic in high levels, but it is important to
determineiftheelevationduetoexcessvitaminsupplements
since the other causes of a high vitamin B12 level are
usually serious such as solid tumours, blood diseases, liver
diseases and kidney diseases. The aim of this article is to
review the association between hypercobalaminemia and
malignancy & hematological disorders. The association
of hypercobalaminemia and solid tumours was first
described and documented by Carmel et al. in 1975 and
in 1977. In ancient literature hypercobalaminemia is an
anomaly frequently observed in malignant blood diseases
including chronic myelomonocytic leukemia, primary
hypereosinophilic syndrome, myelodysplastic syndromes
and acute leukemias. In the series of Chiche et al., 23% of
patientswith high serumcobalamin had a solid cancer, which
was previously unknown in 73% of cases and still at a non-
metastatic stage in 80% of cases. In their work, Chiche et al.
found a statistically significant association between vitamin
B12 levels >1275 pg/ml and the existence of a malignant
blood disease. According to a September 2012 study in "PLoS
One," people with high vitamin B12 had a 4- to 18-times
higher risk of having a blood disease. Table 1 summarizes the
key data in the literature regarding high serum cobalamin
observed in malignancy and hematological disorders.
Based on, we can conclude that: it is possible to depend
on hypercobalaminemia as non specific early marker in the
working diagnosis ofmalignancy and hematological disorder.
Speaker Biography
Abdou Deyab is belongs to Egypt. He has his expertise in evaluation and
passion in improving the health and wellbeing. He comes with over 12
years of experience in the practice and research work of general pediatrics
and pediatric haematology oncology in Egypt, Kuwait and Oman. He held
the position of specialist pediatrician.
e:
DISEASE ASSOCIATED HYPERCOBALAMINEMIA ETIOLOGY
CML Very frequent ( up to 10 times normal
value)
Production of granulocyte HCs.
ALs -promyelocytic 30% of cases Production of granulocyte HCs
Polycythemia vera(PV) 30–50% of cases Release of granulocyte HCs
Primary myelofibrosis one-third of cases Elevated apo-HC and apo-TCB II levels
Primary HES Up to 30 times normal value Production of granulocyte HCs.
HCC 50 % of cases Production of HCs by the tumour or
hyperleukocytosis
Association between hypercobalaminemia and malignancies & haematological disorders
J Med Oncl Ther| Volume 4